Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

Alberto Borghetti; Annalisa Mondi; B Piccoli; Roberta Gagliardini; S Lamonica; Nicoletta Ciccarelli; Alessandro D'Avino; Federico Pallavicini; Roberto Cauda; Andrea De Luca; Massimiliano Fabbiani; Simona Di Giambenedetto

doi:10.7448/IAS.17.4.19817

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

Alberto Borghetti, Annalisa Mondi, B Piccoli, Roberta Gagliardini, S Lamonica, Nicoletta Ciccarelli, Alessandro D'Avino, Federico Pallavicini, Roberto Cauda, Andrea De Luca, Massimiliano Fabbiani, Simona Di Giambenedetto

Research output: Contribution to journal › Conference article › peer-review

Abstract

According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.

Original language	English
Pages (from-to)	19817-19817
Number of pages	1
Journal	Journal of the International AIDS Society
Volume	17
DOIs	https://doi.org/10.7448/IAS.17.4.19817
Publication status	Published - 2014
Event	HIV Drug Therapy Glasgow Congress 2014 - Glasgow Duration: 2 Nov 2014 → 6 Nov 2014

Keywords

HIV
therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7448/IAS.17.4.19817

Cite this

Borghetti, A., Mondi, A., Piccoli, B., Gagliardini, R., Lamonica, S., Ciccarelli, N., D'Avino, A., Pallavicini, F., Cauda, R., De Luca, A., Fabbiani, M., & Di Giambenedetto, S. (2014). Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. Journal of the International AIDS Society, 17, 19817-19817. https://doi.org/10.7448/IAS.17.4.19817

@article{34616898ed9642228b4f32f41ca074a8,

title = "Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre",

abstract = "According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.",

keywords = "HIV, therapy, HIV, therapy",

author = "Alberto Borghetti and Annalisa Mondi and B Piccoli and Roberta Gagliardini and S Lamonica and Nicoletta Ciccarelli and Alessandro D'Avino and Federico Pallavicini and Roberto Cauda and {De Luca}, Andrea and Massimiliano Fabbiani and {Di Giambenedetto}, Simona",

year = "2014",

doi = "10.7448/IAS.17.4.19817",

language = "English",

volume = "17",

pages = "19817--19817",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "John Wiley & Sons Inc.",

note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 02-11-2014 Through 06-11-2014",

}

Borghetti, A, Mondi, A, Piccoli, B, Gagliardini, R, Lamonica, S, Ciccarelli, N, D'Avino, A, Pallavicini, F, Cauda, R, De Luca, A, Fabbiani, M & Di Giambenedetto, S 2014, 'Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre', Journal of the International AIDS Society, vol. 17, pp. 19817-19817. https://doi.org/10.7448/IAS.17.4.19817

TY - JOUR

T1 - Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

AU - Borghetti, Alberto

AU - Mondi, Annalisa

AU - Piccoli, B

AU - Gagliardini, Roberta

AU - Lamonica, S

AU - Ciccarelli, Nicoletta

AU - D'Avino, Alessandro

AU - Pallavicini, Federico

AU - Cauda, Roberto

AU - De Luca, Andrea

AU - Fabbiani, Massimiliano

AU - Di Giambenedetto, Simona

PY - 2014

Y1 - 2014

N2 - According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.

AB - According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.

KW - HIV

KW - therapy

KW - HIV

KW - therapy

UR - http://hdl.handle.net/10807/61162

U2 - 10.7448/IAS.17.4.19817

DO - 10.7448/IAS.17.4.19817

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19817

EP - 19817

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow Congress 2014

Y2 - 2 November 2014 through 6 November 2014

ER -

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this